Find a Physician | How to Contribute | About Us | Clinical Trials
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial NU UCSF12I01

Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma (124511)
Principal Investigator
Halla Nimeiri
  • Status: CLOSED
  • Study Type: Therapeutic
  • Protocol No:.NU UCSF12I01
The purpose of this study is to find out what effects (good and/or bad)the drug combination of Temsirolimus and Sorafenib has on advanced hepatocellular carcinoma (HCC).
HCC is a liver cancer that cannot be removed by surgery. Sorafenib is the standard treatment for HCC. Sorafenib works by turning off some of the chemicals in the tumor cells that let the tumor grow new blood vessels. Temsirolimus works by turning off some of the chemicals that help cells grow and divide. An earlier study (Phase 1) shows promise that the addition of Temsirolimus will make Sorafenib more effective in the treatment of HCC. Temsirolimus is approved by Food & Drug Administration (FDA) for treatment of kidney cancer but it's use in treating HCC is considered experimental.
Some of the eligibility criteria include:
  • Participants must be 18 years of age or older
  • Participants must have advanced inoperable hepatocellular carcinoma.
  • Participants may not have had prior chemotherapy for their HCC.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
Participants will take both Sorafenib and Temsirolimus for a 28 day cycle. Particpants will be assessed for results after each cycle. Treatment will continue for participants until their disease worsens, they experience unacceptable side effects, or the study doctor decides it is in their best interest to be removed from the study.
Clinical Trials Recruitment Nurse
Robert H. Lurie Comprehensive Cancer Center

Find Related Clinical Trials

Browse by Disease Sites

last updated: 26-Sep-17 12:30 AM


Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.